COVAXX gets supply deals worth $2.8 billion for potential Covid-19 vaccine
The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.
COVAXX, a unit of United Biomedical Inc, said on Thursday it has received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador.
The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.
The US based company signed an agreement in September with Brazilian lab and hospital group DASA S.A. to conduct mid-to-late stage trials in Brazil for the vaccine.
COVAXX estimates it can produce 100 million doses in first half of next year and 1 billion by end of 2021.
Last month, the company signed a logistics partnership with Maersk for transportation and supply chain services that will be needed to deliver the vaccine around the world.
Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.